Re-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors.
Benjamin M SciricaKyungAh ImSabina A MurphyJulia F KuderDolly A RodriguezRenato D LopesJennifer B GreenChristian T RuffMarc S SabatinePublished in: Clinical cardiology (2022)
The results of this independent re-adjudication process and analyses of CV outcomes from TECOS were consistent with the original adjudication results and overall study findings. An updated study-level meta-analysis showed no overall significant risk for HHF with DPP-4 inhibitors, but with statistical heterogeneity.